Login to Your Account

Deal Worth Up to $300M

Sideris: $32M Series A Round, Novartis Could Buy Company

By Randy Osborne
Staff Writer

Wednesday, October 23, 2013
Not yet fully emerged from stealth mode, Sideris Pharmaceuticals Inc. made known its $32 million Series A round as well as a potential $300 million deal with Novartis AG that includes the right to acquire Sideris and the iron-chelating candidate SP-420.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription